Skip to main content
    G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.02
    -0.03 (-0.98%)

    Market Cap: $307.59M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Galectin Therapeutics Inc (GALT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Galectin Therapeutics are Greenwich Lifesciences (GLSI), Tectonic Therapeutic (TECX) and Larimar Therapeutics (LRMR). By market cap, Galectin Therapeutics ranks 6th of the 13 companies on this page; Shattuck Labs (STTK) is the largest at $473.57M.

    Peer Comparison

    GALT's ROIC of 671.1% is above the peer median of -6.7%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Galectin Therapeutics (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    Larimar Therapeutics Inc (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Alector Inc (ALEC)$378.15M7.3x1.7x23.9%N/A4896.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Cartesian Therapeutics Inc. (RNAC)$193.69MN/A179.8x0.0%147.2%-92.9%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Nautilus Biotechnology Inc (NAUT)$295.50MN/A630.2x0.0%N/A0.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Shattuck Labs Inc (STTK)$473.57MN/AN/A0.0%N/A-66.6%0.00%
    Cellectis SA (CLLS)$118.86MN/A1.8x0.0%-74.1%-85.4%0.00%
    Peer median$291.73M9.7x3.8x0.0%-6.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Galectin Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors
    Larimar Therapeutics Inc (LRMR)
    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases.
    LRMR competitors
    Alector Inc (ALEC)
    Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases.
    ALEC competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Cartesian Therapeutics Inc. (RNAC)
    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs...
    RNAC competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Nautilus Biotechnology Inc (NAUT)
    Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome...
    NAUT competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Shattuck Labs Inc (STTK)
    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States.
    STTK competitors
    Cellectis SA (CLLS)
    Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors...
    CLLS competitors

    Frequently Asked Questions About GALT

    Who are Galectin Therapeutics' main competitors?

    The companies most similar to Galectin Therapeutics include Greenwich Lifesciences (GLSI), Tectonic Therapeutic (TECX), Larimar Therapeutics (LRMR), Alector (ALEC) and Fulcrum Therapeutics (FULC), listed from the closest match.

    Who is Galectin Therapeutics' biggest competitor?

    Shattuck Labs (STTK) is the largest of the similar companies at $473.57M; Greenwich Lifesciences (GLSI) is the closest match by business profile, size, sector and industry.

    How does GALT stock compare with its competitors?

    GALT's net margin is 0.0% against a peer median of 0.0%.

    Which of Galectin Therapeutics' competitors pays a higher dividend?

    Galectin Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Galectin Therapeutics bigger than its competitors?

    No. Galectin Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Shattuck Labs (STTK) at $473.57M.